SBFM breakout on blockbuster news yesterday

Published: Fri, 12/04/20

Subscribers,

Today's ticker is a brand new trade idea for us and our readers.

It has a very recent history of making big short term gains and just yesterday the Company announced big news that should excite investors and traders alike.

It's time to get Sunshine Biopharma, Inc (SBFM) on your radar immediately.

SBFM made a 600% run back in July this year over just a few days. It then gained 100% in one day in August and a 200% gain in one day back in September, followed by more substantial one day gains in October and just yesterday.

And with a tiny market cap of just $4.5m (per OTCMarkets.com), its no wonder it delivers epic moves.

Put simply, SBFM is a trader's dream come true.

About SBFM...

Sunshine Biopharma is a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Coronavirus Treatment in Development

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.

On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease (Mpro), an enzyme that is essential for viral replication.
In August, 2020, we completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in our patent application filed on May 22, 2020.
In September, 2020, we completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and Interim Associate Head of Pharmaceutical and Biomedical Sciences.
In October 2020, we expanded our collaboration with Dr. Scott Pegan by entering into a research agreement with the University of Georgia to further develop our Anti-Coronavirus lead compound, SBFM-PL4. Together, we will proceed to conduct the in vitro studies followed by cell culture assays and assessment in Coronavirus infected mice before entering human clinical trials.

Adva-27a - Our Flagship Anticancer Drug

Our flagship anticancer compound is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer (See 3D Molecular Model below). Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast cancer following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. Unlike other antitumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells. Adva-27a is very effective against multidrug resistant breast cancer cells while Etoposide, another Topoisomerase II inhibitor, has no activity against this aggressive form of cancer (see Figure below). In other studies, Adva-27a showed cell killing activity in various other types of multidrug resistant cancer cells.

Generic Pharmaceuticals

Sunshine Biopharma has licensing agreements for the following four (4) generic prescription drugs:

– Anastrozole for treatment of Breast Cancer
– Letrozole for treatment of Breast Cancer
– Bicalutamide for treatment of Prostate Cancer
– Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)

These drugs will be available in Canadian pharmacies soon.

You can learn more about SBFM at their website https://sunshinebiopharma.com/

Breaking News...

Sunshine Biopharma Pays Off Convertible Notes in Cash Preventing New Shares From Hitting the Market

MONTREAL, QC / ACCESSWIRE / December 3, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off just over $100,000 worth of convertible notes associated with the Company. Our Board of Directors deemed this action to be a priority for the Company in order to mitigate dilutive conversions and maximize shareholder value.

Sunshine Biopharma's CFO, Camille Sebaaly stated, "We are pleased to have paid off this convertible debt within the required time frame and will continue to work towards our overall goal of growth from the operational side of the business." We always have our shareholders best interests in mind," he added.

Read in full at https://finance.yahoo.com/news/sunshine-biopharma-pays-off-convertible-130000473.html

Sunshine Biopharma Receives Third Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment

MONTREAL, QC / ACCESSWIRE / December 1, 2020 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the third tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $800,000 that the Company has received under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.

Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, "We continue to be amazed by both the ingenuity and the work ethic of Sunshine Biopharma's leadership team. This is money well spent as every dollar is dedicated to the understanding and advancement of life-saving medicines. RB Capital is proud to invest in a company that is relentlessly working towards developing a Coronavirus treatment. The implications of such a treatment are boundless."

Sunshine Biopharma Inc. CFO, Camille Sebaaly shared, "We have a lot of important work under way, and the continued funding by RB Capital Partners enables us to keep our focus on the advancement of our oncology and antiviral drugs. We look forward to continue working with them as it is clear that they truly believe in our Company's vision."

Read in full at https://finance.yahoo.com/news/sunshine-biopharma-receives-third-tranche-130000018.html

Get SBFM on your screen immediately, do your research and be ready for an exciting trading day ahead.

All the best.

SmallCapMomo.com

picks@smallcapmomo.com

--------------------------------------------------------------------------------------------------------

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.

Disclaimer
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here. SmallCapMomo.com is the property of Alpha Stock Media. SmallCapMomo.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapMomo.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. SmallCapMomo.com does not offer such advice or analysis, and SmallCapMomo.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, SmallCapMomo.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SmallCapMomo.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapMomo.com is not responsible for any claims made by the companies advertised herein. SmallCapMomo.com may receive compensation and they, its employees and/or affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in SmallCapMomo.com statements and opinions and such statements and opinions cannot be considered independent. SmallCapMomo.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, SmallCapMomo.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. SmallCapMomo.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to close positions they have entered into at any given time including before or after the release of the companies profile. Alpha Stock Media has been compensated one thousand dollars via electronic transfer from a non-affiliated third party for the profile of SBFM. SmallCapMomo.com does not accept compensation in restricted or free-trading shares for its marketing services of the company being profiled. However the third party that has compensated SmallCapMomo.com may hold free-trading shares of the company being profiled and could very well be selling shares of the company’s stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. If SmallCapMomo.com ever does accept compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the position of those free trading shares received as compensation for our services at the time our promotional material is released to the public, as well as information on our intention to sell these shares during the promotional period or thereafter.